High Court to hear former Supermax MD Stanley Thai's appeal on Sept 29

(theedgemarkets.com / August 14, 2020 10:54 am +08)

KUALA LUMPUR (Aug 14): The High Court here today fixed Sept 29 to hear the appeal of former Supermax Corp Bhd group managing director Datuk Seri Stanley Thai Kim Sim and former remisier Tiong Kiong Choon who had each been sentenced to five years' jail and fined for insider trading in relation to APL Industries Bhd (APLI).

Besides his stint at the rubber glove manufacturer, Thai is also a former chief executive officer (CEO) of APLI.

High Court Judicial Commissioner Datuk Azhar Abdul Hamid fixed the date to hear the appeal.

Thai was represented by lawyer Shamsul Sulaiman, while lawyer Datuk Mohd Yusof Zainal Abiden represented Tiong.

Securities Commission Malaysia (SC) Deputy Public Prosecutor (DPP) Mohd Hafiz Mohd Yusoff appeared for the prosecution.

On Nov 24, 2017, the Sessions Court here convicted Thai and Tiong of insider trading offences, according to the SC’s statement then.

The SC said Thai was sentenced to a five-year jail term and fined RM5 million, while Tiong was sentenced to five years' jail and fined RM10 million.

Insider trading offences, under Section 188 of the Capital Markets and Services Act 2007 (CMSA), carry a mandatory punishment of imprisonment not exceeding 10 years and a fine of not less than RM1 million, the SC said.

"Thai was convicted of communicating non-public information between Oct 26 and 29, 2007 to Tiong. Tiong was convicted of two counts of disposing of a total of 6.21 million (6,208,500) APLI shares while in possession of the same non-public information via accounts belonging to his mother-in-law and his mother. At the time of the commission of the offences, Tiong was also a licensed intraday trader with a stockbroking company.

"The non-public information communicated from Thai to Tiong related to the audit adjustments proposed by APLI’s auditors resulted in APLI reporting a higher loss for the financial year ended June 30, 2007, as compared to the previously reported unaudited 4Q (fourth-quarter) results for the same financial year, and that APLI would be classified as a PN17 (Practice Note 17) company. APLI made announcements to Bursa Malaysia Securities Bhd about the audit adjustments and its classification as a PN17 company on Oct 31, 2007,” the SC said.

The SC said that in passing the sentences, Sessions Court Judge Zulqarnain Hassan ruled that a deterrent sentence was warranted as insider trading offences were deemed more serious than conventional crimes, given the far-reaching effects on investors’ confidence and the public as a whole.

Justice Zulqarnain was quoted as saying in the statement: “Insider trading is a modern white-collar economic crime. It is serious and in a category or class of its own.”

According to the SC, the convictions came after a full trial where 14 witnesses testified for the prosecution, while four witnesses testified for the defence.


##https://www.theedgemarkets.com/article/high-court-hear-former-supermax-md-stanley-thais-appeal-sept-29

Russia Says Saudi Arabia Will Test Controversial Virus Vaccine

(August 16, 2020, 3:15 PM GMT+8)

~ UAE, Philippines and Brazil also agreed to test new shot

~ Vaccine has drawn criticism due to rushed regulatory process


Russia has reached an agreement in principle to conduct clinical trials of its controversial coronavirus vaccine in Saudi Arabia and the United Arab Emirates, according to the head of its sovereign wealth fund.

The Russians are working with a pharmaceutical company in the kingdom and have shared data from Phase I and Phase II trials with Saudi partners, the chief executive officer of the Russian Direct Investment Fund, Kirill Dmitriev, told Arab News. The company wasn’t identified.

“We’ll really engage with Saudi scientists and the Saudi Health Ministry,” Dmitriev said. “We believe that Saudi will be a very strong partner for our joint work on the Sputnik V vaccine.”

Earlier this month Russia approved a coronavirus shot before crucial tests have shown it’s safe and effective. The plan is to begin mass inoculation soon. A local association of multinational pharmaceutical companies has called the rushed regulatory approval risky.

Russia also shared its data with the UAE and is expecting to start its trials there later in August, Dmitriev said. Additionally, it plans to conduct clinical trials in the Philippines and Brazil as well as at home, he said.


##https://www.bloomberg.com/news/articles/2020-08-16/russia-says-saudi-arabia-will-test-controversial-virus-vaccine

Russia Says Saudi Arabia Will Test Controversial Virus Vaccine

(August 16, 2020, 3:15 PM GMT+8)

~ UAE, Philippines and Brazil also agreed to test new shot

~ Vaccine has drawn criticism due to rushed regulatory process


Russia has reached an agreement in principle to conduct clinical trials of its controversial coronavirus vaccine in Saudi Arabia and the United Arab Emirates, according to the head of its sovereign wealth fund.

The Russians are working with a pharmaceutical company in the kingdom and have shared data from Phase I and Phase II trials with Saudi partners, the chief executive officer of the Russian Direct Investment Fund, Kirill Dmitriev, told Arab News. The company wasn’t identified.

“We’ll really engage with Saudi scientists and the Saudi Health Ministry,” Dmitriev said. “We believe that Saudi will be a very strong partner for our joint work on the Sputnik V vaccine.”

Earlier this month Russia approved a coronavirus shot before crucial tests have shown it’s safe and effective. The plan is to begin mass inoculation soon. A local association of multinational pharmaceutical companies has called the rushed regulatory approval risky.

Russia also shared its data with the UAE and is expecting to start its trials there later in August, Dmitriev said. Additionally, it plans to conduct clinical trials in the Philippines and Brazil as well as at home, he said.


##https://www.bloomberg.com/news/articles/2020-08-16/russia-says-saudi-arabia-will-test-controversial-virus-vaccine

Keyman188 foresee a lot of traders & investors will be surprised by this 2 core pharmaceutical firms which dealing with Covid-19 vaccine will be reaching unprecedented level :-

1) Pharma - TP 10.00

2) Dpharma - TP 7.50


Keyman188 looking at long term growth due to following reason (which were highlighted by Minister) :-


1) Two government-linked companies (GLC) which are also pharmaceutical manufacturing facilities have been identified to do the "fill and finish" process for the Covid-19 vaccine once it's available


2) "The two companies have told the government that they are willing to take stock production and prioritise it for the Covid-19 vaccine when it is available.


3) If we have the capacity, we will also offer our fill and finish service to other countries.


-------------------------------------------------------------------------------------------------------------


***Vaccine development very very very close to emerge into market for consumption



^^^ The main profitable driven coming for the next 3 years by vaccine needed at mass market


-------------------------------------------------------------------------------------------------------------


A lot of investors & traders not review the past annual report for Duopharma

Gross Profit margin always can generated by 40% from the revenue

Net profit also improved by 11% to 13% since 2018

Forthcoming financial performance more & more bright of this pharmaceutical firm since already appointed core company dealing with Covid-19 vaccine once available


-------------------------------------------------------------------------------------------------------------



@@ Keyman188 always like to repeat & repeat to remind "old people" like Keyman188 to avoid forgotten........

Keyman188 foresee a lot of traders & investors will be surprised by this 2 core pharmaceutical firms which dealing with Covid-19 vaccine will be reaching unprecedented level :-

1) Pharma - TP 10.00

2) Dpharma - TP 7.50


Keyman188 looking at long term growth due to following reason (which were highlighted by Minister) :-


1) Two government-linked companies (GLC) which are also pharmaceutical manufacturing facilities have been identified to do the "fill and finish" process for the Covid-19 vaccine once it's available


2) "The two companies have told the government that they are willing to take stock production and prioritise it for the Covid-19 vaccine when it is available.


3) If we have the capacity, we will also offer our fill and finish service to other countries.


-------------------------------------------------------------------------------------------------------------


***Vaccine development very very very close to emerge into market for consumption



^^^ The main profitable driven coming for the next 3 years by vaccine needed at mass market


-------------------------------------------------------------------------------------------------------------



@@ Keyman188 always like to repeat & repeat to remind "old people" like Keyman188 to avoid forgotten.......

Mexico needs 200 million COVID-19 vaccine doses; shots could start in April

( Sunday, 16 Aug 2020 4:37 AM MYT )


MEXICO CITY (Reuters) - Mexico will need up to 200 million coronavirus vaccine doses, according to a senior government official, and inoculation of its 120 million inhabitants could start as early as April if clinical trials and regulatory approvals for pharmaceutical firm AstraZeneca Plc go as planned.

In partnership with the governments of Mexico and Argentina, AstraZeneca initially plans to produce 150 million doses in early 2021 and eventually make at least 400 million doses for distribution throughout Latin America. AstraZeneca is among those working on COVID-19 vaccine candidates now in development around the world.

Mexico's government also has said it is considering other options for bringing a vaccine quickly to its population, the second-largest in Latin America.

AstraZeneca will be able to produce between 30 and 35 million vaccines per month, Martha Delgado, a Mexican deputy foreign minister, told Reuters in an interview on Friday.

The vaccine could require two doses to be effective, Delgado said.

"If we need 200 million, we're going to be vaccinating for a long time," Delgado added.

Last-stage so-called Phase III trials are expected to conclude by November or December, after which AstraZeneca will seek government approvals if the vaccine is found to be safe and effective. If that goes smoothly, Delgado estimated the first vaccines in Mexico could be administered in April.

Mexico's death toll of 55,908 stands as the world's third highest, behind the United States and Brazil. Latin America's 6 million cases and more than 237,000 deaths make it the world's hardest-hit region.

To ensure all Mexicans have access to a vaccine, President Andres Manuel Lopez Obrador's government is in talks with other pharmaceutical laboratories in different stages of developing a vaccine.

"Astra's production isn't going to be enough for Mexico. We need to supplement that with a couple of more vaccines," Delgado said.

Mexico's government has completed memorandums of understanding with French drugmaker Sanofi, Johnson & Johnson's Janssen unit and Chinese companies CanSino Biologics Inc and Walvax Biotechnology Co Ltd.

CanSino and Walvax are interested in producing a vaccine in Mexico for delivery to the Latin American market.

Mexico's health authorities are evaluating the Phase I and II clinical trials of those four companies and will determine the viability of Phase III studies in Mexico in the coming weeks, Delgado said. The earlier phase trials represent an initial test of a vaccine's safety and effectiveness among small numbers of subjects.

To save time, Mexico's federal health regulator COFEPRIS will start analyzing AstraZeneca's completed studies and accelerate approvals if Phase III is successful.

"This is the country's strategy to diversify our possibilities of having access to the vaccine as soon as possible ... and obviously at an affordable cost for the country," Delgado said.


##https://www.thestar.com.my/news/world/2020/08/16/mexico-needs-200-million-covid-19-vaccine-doses-shots-could-start-in-april

Mexico needs 200 million COVID-19 vaccine doses; shots could start in April

( Sunday, 16 Aug 2020 4:37 AM MYT )


MEXICO CITY (Reuters) - Mexico will need up to 200 million coronavirus vaccine doses, according to a senior government official, and inoculation of its 120 million inhabitants could start as early as April if clinical trials and regulatory approvals for pharmaceutical firm AstraZeneca Plc go as planned.

In partnership with the governments of Mexico and Argentina, AstraZeneca initially plans to produce 150 million doses in early 2021 and eventually make at least 400 million doses for distribution throughout Latin America. AstraZeneca is among those working on COVID-19 vaccine candidates now in development around the world.

Mexico's government also has said it is considering other options for bringing a vaccine quickly to its population, the second-largest in Latin America.

AstraZeneca will be able to produce between 30 and 35 million vaccines per month, Martha Delgado, a Mexican deputy foreign minister, told Reuters in an interview on Friday.

The vaccine could require two doses to be effective, Delgado said.

"If we need 200 million, we're going to be vaccinating for a long time," Delgado added.

Last-stage so-called Phase III trials are expected to conclude by November or December, after which AstraZeneca will seek government approvals if the vaccine is found to be safe and effective. If that goes smoothly, Delgado estimated the first vaccines in Mexico could be administered in April.

Mexico's death toll of 55,908 stands as the world's third highest, behind the United States and Brazil. Latin America's 6 million cases and more than 237,000 deaths make it the world's hardest-hit region.

To ensure all Mexicans have access to a vaccine, President Andres Manuel Lopez Obrador's government is in talks with other pharmaceutical laboratories in different stages of developing a vaccine.

"Astra's production isn't going to be enough for Mexico. We need to supplement that with a couple of more vaccines," Delgado said.

Mexico's government has completed memorandums of understanding with French drugmaker Sanofi, Johnson & Johnson's Janssen unit and Chinese companies CanSino Biologics Inc and Walvax Biotechnology Co Ltd.

CanSino and Walvax are interested in producing a vaccine in Mexico for delivery to the Latin American market.

Mexico's health authorities are evaluating the Phase I and II clinical trials of those four companies and will determine the viability of Phase III studies in Mexico in the coming weeks, Delgado said. The earlier phase trials represent an initial test of a vaccine's safety and effectiveness among small numbers of subjects.

To save time, Mexico's federal health regulator COFEPRIS will start analyzing AstraZeneca's completed studies and accelerate approvals if Phase III is successful.

"This is the country's strategy to diversify our possibilities of having access to the vaccine as soon as possible ... and obviously at an affordable cost for the country," Delgado said.


##https://www.thestar.com.my/news/world/2020/08/16/mexico-needs-200-million-covid-19-vaccine-doses-shots-could-start-in-april

Coronavirus Vaccine Tracker (Updated August 14, 2020)


##https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

Coronavirus Vaccine Tracker (Updated August 14, 2020)


##https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

Covid Vaccine Contender CureVac More Than Triples in DebutBy 

August 14, 2020, 12:40 PM EDTUpdated on August 14, 2020, 4:39 PM EDT


~ CureVac gets biggest first-day gain for 2020 U.S. listing

~ CEO says vaccine race is more against time than rivals


CureVac BV soared 249% in its trading debut after raising $213 million in a U.S. initial public offering that boosted its profile in the race for a coronavirus vaccine.

It was the best first-day performance by a wide margin among about 200 new listings on U.S. exchanges this year, according to data compiled by Bloomberg.

“It is definitely a race,” CureVac Chief Executive Officer Franz-Werner Haas said in a Bloomberg TV interview. “It is a race not that much against the competition of other vaccine producers out there but a race against the virus. It is a race against time.”

The company’s shares closed at $55.90 in New York trading Friday, giving the company a market value of $9.86 billion. CureVac sold 13.33 million shares Thursday for $16 each after marketing them for $14 to $16.

CureVac, based in Tubingen, Germany, is also raising 100 million euros ($118 million) in a private placement concurrent with the IPO, according to CureVac’s filings with the U.S. Securities and Exchange Commission.

Government Stake

The German government agreed in June to acquire 23% of the company for 300 million euros via development bank Kreditanstalt fuer Wiederaufbau, known as KfW.

The offering was led by Bank of America Corp., Jefferies Financial Group Inc. and Credit Suisse Group AG. Shares of the company, which is being incorporated in the Netherlands and renamed CureVac NV in conjunction with the IPO, are trading on the Nasdaq Global Market under the symbol CVAC.

CureVac, founded in 2000, said in June that it received regulatory approval to begin Phase 1 clinical trials of its Covid-19 vaccine candidate. It said in its filing that it expects the results of those trials in the fourth quarter.

As the coronavirus pandemic took hold, CureVac became the prize in a transatlantic competition to secure access to a potential vaccine after reports that the U.S. was angling to buy the company or its technology. In March, CureVac denied speculation that the U.S. government tried to buy the business or its technology.

For More: CureVac Coronavirus Vaccine Cleared for Human Trials in Germany



##https://www.google.com/amp/s/www.bloomberg.com/amp/news/articles/2020-08-14/coronavirus-vaccine-contender-curevac-triples-briefly-in-debut

Covid Vaccine Contender CureVac More Than Triples in DebutBy 

August 14, 2020, 12:40 PM EDTUpdated on August 14, 2020, 4:39 PM EDT


~ CureVac gets biggest first-day gain for 2020 U.S. listing

~ CEO says vaccine race is more against time than rivals


CureVac BV soared 249% in its trading debut after raising $213 million in a U.S. initial public offering that boosted its profile in the race for a coronavirus vaccine.

It was the best first-day performance by a wide margin among about 200 new listings on U.S. exchanges this year, according to data compiled by Bloomberg.

“It is definitely a race,” CureVac Chief Executive Officer Franz-Werner Haas said in a Bloomberg TV interview. “It is a race not that much against the competition of other vaccine producers out there but a race against the virus. It is a race against time.”

The company’s shares closed at $55.90 in New York trading Friday, giving the company a market value of $9.86 billion. CureVac sold 13.33 million shares Thursday for $16 each after marketing them for $14 to $16.

CureVac, based in Tubingen, Germany, is also raising 100 million euros ($118 million) in a private placement concurrent with the IPO, according to CureVac’s filings with the U.S. Securities and Exchange Commission.

Government Stake

The German government agreed in June to acquire 23% of the company for 300 million euros via development bank Kreditanstalt fuer Wiederaufbau, known as KfW.

The offering was led by Bank of America Corp., Jefferies Financial Group Inc. and Credit Suisse Group AG. Shares of the company, which is being incorporated in the Netherlands and renamed CureVac NV in conjunction with the IPO, are trading on the Nasdaq Global Market under the symbol CVAC.

CureVac, founded in 2000, said in June that it received regulatory approval to begin Phase 1 clinical trials of its Covid-19 vaccine candidate. It said in its filing that it expects the results of those trials in the fourth quarter.

As the coronavirus pandemic took hold, CureVac became the prize in a transatlantic competition to secure access to a potential vaccine after reports that the U.S. was angling to buy the company or its technology. In March, CureVac denied speculation that the U.S. government tried to buy the business or its technology.

For More: CureVac Coronavirus Vaccine Cleared for Human Trials in Germany



##https://www.google.com/amp/s/www.bloomberg.com/amp/news/articles/2020-08-14/coronavirus-vaccine-contender-curevac-triples-briefly-in-debut

Russia produces first batch of COVID-19 vaccine - Interfax

WORLD

Saturday, 15 Aug 2020 4:30 PM MYT

MOSCOW (Reuters) - Russia has produced the first batch of its new vaccine for COVID-19, the Interfax news agency quoted the health ministry as saying on Saturday, hours after the ministry reported the start of manufacturing.

powered by Rubicon Project

Some scientists said they fear that with this fast regulatory approval Moscow may be putting national prestige before safety amid the global race to develop a vaccine against the disease.

Russia has said the vaccine, the first for the coronavirus to go into production, will be rolled out by the end of this month.

Its approval comes before trials that would normally involve thousands of participants, commonly known as Phase III. Such trials are usually considered essential precursors for a vaccine to secure regulatory approval.

The vaccine has been named "Sputnik V" in homage to the world's first satellite launched by the Soviet Union. President Vladimir Putin has assured the public that it is safe, adding that one of his daughters had taken it as a volunteer and felt good afterwards.

Moscow's Gamaleya Institute, which developed the vaccine, said previously that Russia would be producing about 5 million doses a month by December-January, Interfax said.

(Reporting by Polina Devitt; editing by Ros Russell)



##https://www.thestar.com.my/news/world/2020/08/15/russia-starts-production-of-covid-19-vaccine---interfax

Russia produces first batch of COVID-19 vaccine - Interfax

WORLD

Saturday, 15 Aug 2020 4:30 PM MYT

MOSCOW (Reuters) - Russia has produced the first batch of its new vaccine for COVID-19, the Interfax news agency quoted the health ministry as saying on Saturday, hours after the ministry reported the start of manufacturing.

powered by Rubicon Project

Some scientists said they fear that with this fast regulatory approval Moscow may be putting national prestige before safety amid the global race to develop a vaccine against the disease.

Russia has said the vaccine, the first for the coronavirus to go into production, will be rolled out by the end of this month.

Its approval comes before trials that would normally involve thousands of participants, commonly known as Phase III. Such trials are usually considered essential precursors for a vaccine to secure regulatory approval.

The vaccine has been named "Sputnik V" in homage to the world's first satellite launched by the Soviet Union. President Vladimir Putin has assured the public that it is safe, adding that one of his daughters had taken it as a volunteer and felt good afterwards.

Moscow's Gamaleya Institute, which developed the vaccine, said previously that Russia would be producing about 5 million doses a month by December-January, Interfax said.

(Reporting by Polina Devitt; editing by Ros Russell)



##https://www.thestar.com.my/news/world/2020/08/15/russia-starts-production-of-covid-19-vaccine---interfax

Keyman188 foresee a lot of traders & investors will be surprised by this 2 core pharmaceutical firms which dealing with Covid-19 vaccine will be reaching unprecedented level :-

1) Pharma - TP 10.00

2) Dpharma - TP 7.50


Keyman188 looking at long term growth due to following reason (which were highlighted by Minister) :-


1) Two government-linked companies (GLC) which are also pharmaceutical manufacturing facilities have been identified to do the "fill and finish" process for the Covid-19 vaccine once it's available


2) "The two companies have told the government that they are willing to take stock production and prioritise it for the Covid-19 vaccine when it is available.


3) If we have the capacity, we will also offer our fill and finish service to other countries.



^^^ The main profitable driven coming for the next 3 years by vaccine needed at mass market


---------------------------------------------------------------------------------------------------


A lot of investors & traders not review the past annual report for Duopharma

Gross Profit margin always can generated by 40% from the revenue

Net profit also improved by 11% to 13% since 2018

Forthcoming financial performance more & more bright of this pharmaceutical firm since already appointed core company dealing with Covid-19 vaccine once available


---------------------------------------------------------------------------------------------------



@@ Keyman188 always like to repeat & repeat to remind "old people" like Keyman188 to avoid forgotten........

The U.S. has already invested billions in potential coronavirus vaccines. Here’s where the deals stand

(Published Fri, Aug 14 20206:30 AM EDTUpdated Fri, Aug 14 20209:52 AM EDT)


~ So far, the federal government has struck deals with a handful of pharmaceutical giants that have topped roughly $10.79 billion as part of Operation Warp Speed.

~ The operation aims to provide at least 300 million doses of a coronavirus vaccine by January 2021.

~ Moderna, Johnson & Johnson, Pfizer and BioNTech, Sanofi and GlaxoSmithKline, Novavax and AstraZeneca have all received funding from the operation for their vaccines.


The U.S. has doled out billions to develop a vaccine against the coronavirus that has infected more than 5.1 million people across the country, locking in a minimum of 800 million doses as soon as the immunizations are cleared later this year or early next year.

So far, the deals with a handful of pharmaceutical giants have topped roughly $10.79 billion as part of Operation Warp Speed, a program led by several departments within the federal government to accelerate the development, manufacturing, and distribution of vaccines and treatments to fight the coronavirus.

The operation aims to provide at least 300 million doses of a coronavirus vaccine by January 2021. In most of the agreements, the Department of Health and Human Services says the vaccines will be given to the American people for free if part of a vaccine campaign. Once the vaccines are approved, the campaign is intended to quickly deliver them to as many people as possible. The federal government has said it will cover the cost of delivery but health-care providers can charge to administer the vaccine.

“It is likely that at the beginning of next year we would have tens of millions of doses available,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters on a conference call alongside National Institutes of Health Director Dr. Francis Collins on July 27.

“I think as we get into 2021, several months in, that you would have vaccines that would be widely available,” Fauci said.

Experts say some of the top vaccine candidates are already being manufactured “at risk,” meaning the doses are created and prepared for deployment before official approval from the U.S. Food and Drug Administration.

“We are investing in the development and manufacture of the top six vaccine candidates to ensure rapid delivery. The military is ready to go, they’re ready to deliver a vaccine to Americans as soon as one is fully approved by the FDA and we’re very close to that approval,” President Donald Trump said during a news conference at the White House on Tuesday.

The U.S. is only obligated to pay the next tranche of funding if the vaccines are cleared by the Food and Drug Administration.


Cont....



##https://www.cnbc.com/2020/08/14/the-us-has-already-invested-billions-on-potential-coronavirus-vaccines-heres-where-the-deals-stand.html

The U.S. has already invested billions in potential coronavirus vaccines. Here’s where the deals stand

(Published Fri, Aug 14 20206:30 AM EDTUpdated Fri, Aug 14 20209:52 AM EDT)


~ So far, the federal government has struck deals with a handful of pharmaceutical giants that have topped roughly $10.79 billion as part of Operation Warp Speed.

~ The operation aims to provide at least 300 million doses of a coronavirus vaccine by January 2021.

~ Moderna, Johnson & Johnson, Pfizer and BioNTech, Sanofi and GlaxoSmithKline, Novavax and AstraZeneca have all received funding from the operation for their vaccines.


The U.S. has doled out billions to develop a vaccine against the coronavirus that has infected more than 5.1 million people across the country, locking in a minimum of 800 million doses as soon as the immunizations are cleared later this year or early next year.

So far, the deals with a handful of pharmaceutical giants have topped roughly $10.79 billion as part of Operation Warp Speed, a program led by several departments within the federal government to accelerate the development, manufacturing, and distribution of vaccines and treatments to fight the coronavirus.

The operation aims to provide at least 300 million doses of a coronavirus vaccine by January 2021. In most of the agreements, the Department of Health and Human Services says the vaccines will be given to the American people for free if part of a vaccine campaign. Once the vaccines are approved, the campaign is intended to quickly deliver them to as many people as possible. The federal government has said it will cover the cost of delivery but health-care providers can charge to administer the vaccine.

“It is likely that at the beginning of next year we would have tens of millions of doses available,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters on a conference call alongside National Institutes of Health Director Dr. Francis Collins on July 27.

“I think as we get into 2021, several months in, that you would have vaccines that would be widely available,” Fauci said.

Experts say some of the top vaccine candidates are already being manufactured “at risk,” meaning the doses are created and prepared for deployment before official approval from the U.S. Food and Drug Administration.

“We are investing in the development and manufacture of the top six vaccine candidates to ensure rapid delivery. The military is ready to go, they’re ready to deliver a vaccine to Americans as soon as one is fully approved by the FDA and we’re very close to that approval,” President Donald Trump said during a news conference at the White House on Tuesday.

The U.S. is only obligated to pay the next tranche of funding if the vaccines are cleared by the Food and Drug Administration.


Cont....



##https://www.cnbc.com/2020/08/14/the-us-has-already-invested-billions-on-potential-coronavirus-vaccines-heres-where-the-deals-stand.html

Oxford coronavirus vaccine phase III trials to conclude by November, mass production expected by 2021

(Sun Online Desk / 14th August, 2020 03:16:50)

The University of Oxford-AstraZeneca backed novel coronavirus vaccine has been one of the leading vaccine candidates in the global race. The vaccine, currently in phase III of its trials, which was considered to be the first one to get launched for the public in 2020 will be most likely available for public deployment by 2021, according to latest reports.

Currently, phase III clinical trials are being conducted in research facilities across UK, US, Brazil and South Africa. Trials are also expected to start from next week in India in partnership with Serum Institute of India.
The Oxford University backed vaccine, called AZD-12222 was one of the first to head into the human trial stage as well as start late-stage trials. It's also one vaccine, which has found to be "safest" yet by the WHO in the pre-development phase.

Made using a non-replicating viral strain, the most recent development was confirmed by researchers from the Oxford vaccine research institute, quelling any rumours about an early advent related to launching in 2020.

With researchers hopeful of seeing the end of clinical trials by November of early December, Oxford Researchers have also signed an agreement with Mexico and Argentine authorities to scale up production in the first quarter of 2021.

Making the vaccine available for all

The University of Oxford has also signed pacts with global vaccine makers and vaccine federations. WHO also asked top vaccine makers in the race to be a part of its global vaccine alliance, COVAX to ensure equal distribution of the doses for the public.


##https://www.daily-sun.com/post/499388/Oxford-coronavirus-vaccine-phase-III-trials-to-conclude-by-November-mass-production-expected-by-2021

Oxford coronavirus vaccine phase III trials to conclude by November, mass production expected by 2021

(Sun Online Desk / 14th August, 2020 03:16:50)

The University of Oxford-AstraZeneca backed novel coronavirus vaccine has been one of the leading vaccine candidates in the global race. The vaccine, currently in phase III of its trials, which was considered to be the first one to get launched for the public in 2020 will be most likely available for public deployment by 2021, according to latest reports.

Currently, phase III clinical trials are being conducted in research facilities across UK, US, Brazil and South Africa. Trials are also expected to start from next week in India in partnership with Serum Institute of India.
The Oxford University backed vaccine, called AZD-12222 was one of the first to head into the human trial stage as well as start late-stage trials. It's also one vaccine, which has found to be "safest" yet by the WHO in the pre-development phase.

Made using a non-replicating viral strain, the most recent development was confirmed by researchers from the Oxford vaccine research institute, quelling any rumours about an early advent related to launching in 2020.

With researchers hopeful of seeing the end of clinical trials by November of early December, Oxford Researchers have also signed an agreement with Mexico and Argentine authorities to scale up production in the first quarter of 2021.

Making the vaccine available for all

The University of Oxford has also signed pacts with global vaccine makers and vaccine federations. WHO also asked top vaccine makers in the race to be a part of its global vaccine alliance, COVAX to ensure equal distribution of the doses for the public.


##https://www.daily-sun.com/post/499388/Oxford-coronavirus-vaccine-phase-III-trials-to-conclude-by-November-mass-production-expected-by-2021

China Sinopharm's potential COVID-19 vaccine triggers antibodies in clinical trials (14 Aug 2020 04:07PM)

BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.

The potential vaccine has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.

Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 trial expected to recruit 15,000 people, as China has too few new cases to be a useful trial site.

The state-owned company will also supply the candidate to Pakistan as part of a trial agreement, the Wall Street Journal reported.

The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
Advertisement

The results were based on data from 320 healthy adults in Phase 1 and 2 trials.

The candidate triggered robust antibody responses in inoculated people, but it remained unknown if that was sufficient to prevent COVID-19 infection, researchers developing the vaccine said in the paper.

Sinopharm's chairman told state media last month that a potential vaccine could be ready by the end of this year with Phase 3 testing expected to be completed in about three months.

The novel coronavirus, which has killed more than 750,000 people globally, has prompted a race to develop a vaccine. More than 150 candidate vaccines are being developed and tested around the world.

Russia became the first country to grant regulatory approval to a vaccine after less than two months of human testing, and a shot developed by Chinese firm CanSino Bilogics has been cleared for use in the military.

China is leading the development of at least eight vaccine candidates in different stages of clinical trials.



##https://www.channelnewsasia.com/news/asia/china-sinopharm-covid-19-vaccine-triggers-antibodies-trials-13020856

China Sinopharm's potential COVID-19 vaccine triggers antibodies in clinical trials (14 Aug 2020 04:07PM)

BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.

The potential vaccine has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.

Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 trial expected to recruit 15,000 people, as China has too few new cases to be a useful trial site.

The state-owned company will also supply the candidate to Pakistan as part of a trial agreement, the Wall Street Journal reported.

The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
Advertisement

The results were based on data from 320 healthy adults in Phase 1 and 2 trials.

The candidate triggered robust antibody responses in inoculated people, but it remained unknown if that was sufficient to prevent COVID-19 infection, researchers developing the vaccine said in the paper.

Sinopharm's chairman told state media last month that a potential vaccine could be ready by the end of this year with Phase 3 testing expected to be completed in about three months.

The novel coronavirus, which has killed more than 750,000 people globally, has prompted a race to develop a vaccine. More than 150 candidate vaccines are being developed and tested around the world.

Russia became the first country to grant regulatory approval to a vaccine after less than two months of human testing, and a shot developed by Chinese firm CanSino Bilogics has been cleared for use in the military.

China is leading the development of at least eight vaccine candidates in different stages of clinical trials.



##https://www.channelnewsasia.com/news/asia/china-sinopharm-covid-19-vaccine-triggers-antibodies-trials-13020856

EU reaches deal with AstraZeneca for at least 300 million doses of potential Covid-19 vaccine

PUBLISHED FRI, AUG 14 20206:33 AM EDT

~ The European Commission has reached a deal with AstraZeneca for the purchase of at least 300 million doses of its potential Covid-19 vaccine.

~ The Commission said the deal also included an option to purchase 100 million more doses.


The European Commission said on Friday it had reached a deal with British pharmaceutical firm AstraZeneca for the purchase of at least 300 million doses of its potential Covid-19 vaccine.

The EU’s executive arm, which is negotiating on behalf of the 27 EU states, said the deal also included an option to purchase 100 million more doses should the vaccine prove safe and effective.


##https://www.cnbc.com/2020/08/14/eu-astrazeneca-vaccine-deal.html

EU reaches deal with AstraZeneca for at least 300 million doses of potential Covid-19 vaccine

PUBLISHED FRI, AUG 14 20206:33 AM EDT

~ The European Commission has reached a deal with AstraZeneca for the purchase of at least 300 million doses of its potential Covid-19 vaccine.

~ The Commission said the deal also included an option to purchase 100 million more doses.


The European Commission said on Friday it had reached a deal with British pharmaceutical firm AstraZeneca for the purchase of at least 300 million doses of its potential Covid-19 vaccine.

The EU’s executive arm, which is negotiating on behalf of the 27 EU states, said the deal also included an option to purchase 100 million more doses should the vaccine prove safe and effective.


##https://www.cnbc.com/2020/08/14/eu-astrazeneca-vaccine-deal.html

1st - Haircut selling price

2nd - Contra trading banned

Final - Designated Securities imposed

1st - Haircut selling price

2nd - Contra trading banned

Final - Designated Securities imposed

1st - Haircut selling price

2nd - Contra trading banned

Final - Designated Securities imposed

1st - Haircut selling price

2nd - Contra trading banned

Final - Designated Securities imposed

##https://www.usnews.com/news/world/articles/2020-08-14/novavax-to-deliver-60-million-doses-of-covid-19-vaccine-candidate-to-uk-for-trial

Novavax to Deliver 60 Million Doses of COVID-19 Vaccine Candidate to UK for Trial

By Reuters, Wire Service Content Aug. 14, 2020, at 1:11 a.m.

(Reuters) - U.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.

The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.

The trial will be a study in about 9,000 adults between 18 years and 85 years of age.

Novavax would partner with Fujifilm Diosynth Biotechnologies for manufacturing the antigen component of its COVID-19 vaccine candidate in the UK, it added.

The company is also gearing up to deliver 100 million doses to the United States by January after it was awarded $1.6 billion to cover testing and manufacturing of its potential vaccine in the country.

Novavax has received $2 billion in funding so far for its coronavirus vaccine, including $384 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Novavax will supply the NVX-CoV2373 doses to the UK beginning as early as the first quarter of 2021, while phase 3 trial is expected to begin in the third quarter of this year, the company said.

The Fujifilm Diosynth Biotechnologies site in the UK is expected to produce about 180 million doses annually, it added.

The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing.

There are currently no approved vaccines for COVID-19, with over 25 candidates being studied in humans.

In an early-stage trial, Novavax's vaccine candidate, NVX-CoV2373, has produced higher levels of antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was "well tolerated" overall.


##https://www.usnews.com/news/world/articles/2020-08-14/novavax-to-deliver-60-million-doses-of-covid-19-vaccine-candidate-to-uk-for-trial

Novavax to Deliver 60 Million Doses of COVID-19 Vaccine Candidate to UK for Trial

By Reuters, Wire Service Content Aug. 14, 2020, at 1:11 a.m.

(Reuters) - U.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.

The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.

The trial will be a study in about 9,000 adults between 18 years and 85 years of age.

Novavax would partner with Fujifilm Diosynth Biotechnologies for manufacturing the antigen component of its COVID-19 vaccine candidate in the UK, it added.

The company is also gearing up to deliver 100 million doses to the United States by January after it was awarded $1.6 billion to cover testing and manufacturing of its potential vaccine in the country.

Novavax has received $2 billion in funding so far for its coronavirus vaccine, including $384 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Novavax will supply the NVX-CoV2373 doses to the UK beginning as early as the first quarter of 2021, while phase 3 trial is expected to begin in the third quarter of this year, the company said.

The Fujifilm Diosynth Biotechnologies site in the UK is expected to produce about 180 million doses annually, it added.

The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing.

There are currently no approved vaccines for COVID-19, with over 25 candidates being studied in humans.

In an early-stage trial, Novavax's vaccine candidate, NVX-CoV2373, has produced higher levels of antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was "well tolerated" overall.


##https://www.usnews.com/news/world/articles/2020-08-14/novavax-to-deliver-60-million-doses-of-covid-19-vaccine-candidate-to-uk-for-trial

Novavax to Deliver 60 Million Doses of COVID-19 Vaccine Candidate to UK for Trial

By Reuters, Wire Service Content Aug. 14, 2020, at 1:11 a.m.

(Reuters) - U.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.

The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.

The trial will be a study in about 9,000 adults between 18 years and 85 years of age.

Novavax would partner with Fujifilm Diosynth Biotechnologies for manufacturing the antigen component of its COVID-19 vaccine candidate in the UK, it added.

The company is also gearing up to deliver 100 million doses to the United States by January after it was awarded $1.6 billion to cover testing and manufacturing of its potential vaccine in the country.

Novavax has received $2 billion in funding so far for its coronavirus vaccine, including $384 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Novavax will supply the NVX-CoV2373 doses to the UK beginning as early as the first quarter of 2021, while phase 3 trial is expected to begin in the third quarter of this year, the company said.

The Fujifilm Diosynth Biotechnologies site in the UK is expected to produce about 180 million doses annually, it added.

The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing.

There are currently no approved vaccines for COVID-19, with over 25 candidates being studied in humans.

In an early-stage trial, Novavax's vaccine candidate, NVX-CoV2373, has produced higher levels of antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was "well tolerated" overall.

Q1 - Net profit dropped by 64%

Q2 - Expected very very red & ugly performance


** Not the right time to bet in

## Very very high possibility soon break below RM 1.80

Don't so fast....

Long way to go...........

Coming soon this counter will be surprised by investors & traders to reach RM 1.85 ~ RM 2.00....

Why???

Simply calculation only...

Currently holding rubberex by 50%.......

If based on glove maker PE...

If based on 40 times PE...

This company at least can shot up to RM 1.85....

OMG...Unexpected after result come out become limit down to 17.44 today

Lai...lai...lai...

Please spread more & more negative news to pressure down everyday......

Tomorrow still can selling more ???......

Mad mad traders waiting for you......

Keyman188 now pegging you......please please coming down....please please pressure more......

Lai...lai...lai...

Lai...lai...lai....Don't talk 3 talk 4 talk cock....

Long waiting for que level...

3.91 (done)

3.86 (done)

3.81 (done)

3.76 (done)

3.71 (done)

3.66 (done)

3.61

3.56

3.51

3.46

3.41

3.36

3.31

3.26

3.21

3.16

3.11

3.06


Keyman188 still holding old batch @ 3.03 since March'20 turbulence time until now...

Keyman188 always is the mad mad investors + traders......

Other people pandemic selling down....Keyman188 always madness collecting falling knight.....


kekeke...kekeke...kekeke...


Lai...lai...lai

Keyman188 foresee a lot of traders & investors will be surprised by this 2 core pharmaceutical firms which dealing with Covid-19 vaccine will be reaching unprecedented level :-

1) Pharma - TP 10.00

2) Dpharma - TP 7.50


Keyman188 looking at long term growth due to following reason (which were highlighted by Minister) :-


1) Two government-linked companies (GLC) which are also pharmaceutical manufacturing facilities have been identified to do the "fill and finish" process for the Covid-19 vaccine once it's available


2) "The two companies have told the government that they are willing to take stock production and prioritise it for the Covid-19 vaccine when it is available.


3) If we have the capacity, we will also offer our fill and finish service to other countries.


---------------------------------------------------------------------------------------------------


A lot of investors & traders not review the past annual report for Duopharma

Gross Profit margin always can generated by 40% from the revenue

Net profit also improved by 11% to 13% since 2018

Forthcoming financial performance more & more bright of this pharmaceutical firm since already appointed core company dealing with Covid-19 vaccine once available


---------------------------------------------------------------------------------------------------



@@ Keyman188 always like to repeat & repeat to remind "old people" like Keyman188 to avoid forgotten........


## Hopefully for those so negative of this company, faster contribute to Keyman188 every trading day......

Coronavirus Vaccine Trials Advance in Race for Covid-19 Protection

Moderna, AstraZeneca and China's CanSino are among the leading candidates to produce a shot to fight the pandemic.

Updated: July 31, 2020, 9:45 PM


The global push to develop and secure coronavirus vaccines is accelerating, with researchers reporting positive developments in early studies and countries signing deals to lock up supplies.

More than 160 vaccines are under development globally, spurred by the U.S. government's Operation Warp Speed program and other fast-track initiatives. Shots from the University of Oxford with AstraZeneca Plc, Moderna Inc. and a partnership of Pfizer Inc. and BioNTech SE are among the vanguard. China's CanSino Biologics has received authorization for a limited deployment of its shot among the Chinese military, and the Russian Defense Ministry has suggested its state-backed vaccine candidate could soon be ready for use.

Progress on treating those already infected has been slower, with Gilead Sciences Inc.'s remdesivir receiving an emergency use authorization in the U.S. and decades-old generic drug dexamethasone showing promise in studies. Here's the current state of play on vaccines and treatments.


##https://www.bloomberg.com/features/2020-coronavirus-drug-vaccine-status/?srnd=premium-asia

Coronavirus Vaccine Trials Advance in Race for Covid-19 Protection

Moderna, AstraZeneca and China's CanSino are among the leading candidates to produce a shot to fight the pandemic.

Updated: July 31, 2020, 9:45 PM


The global push to develop and secure coronavirus vaccines is accelerating, with researchers reporting positive developments in early studies and countries signing deals to lock up supplies.

More than 160 vaccines are under development globally, spurred by the U.S. government's Operation Warp Speed program and other fast-track initiatives. Shots from the University of Oxford with AstraZeneca Plc, Moderna Inc. and a partnership of Pfizer Inc. and BioNTech SE are among the vanguard. China's CanSino Biologics has received authorization for a limited deployment of its shot among the Chinese military, and the Russian Defense Ministry has suggested its state-backed vaccine candidate could soon be ready for use.

Progress on treating those already infected has been slower, with Gilead Sciences Inc.'s remdesivir receiving an emergency use authorization in the U.S. and decades-old generic drug dexamethasone showing promise in studies. Here's the current state of play on vaccines and treatments.


##https://www.bloomberg.com/features/2020-coronavirus-drug-vaccine-status/?srnd=premium-asia

@shareinvestor88..why you delete your post again ???

why?? You scare karma definitely come to see you very very soon !!!...

Here is free to comment...free to talk...

But don't always simply using member name put at your comment...

Next time you still using Keyman188 as your accuse to comment, more & more karma very very soon to see you....

Too sad to say, you did the mistake end up your family need to follow your suit always incurred karma......kesian...kesian...

Keyman188 when to buy...how to buy...why Keyman188 wanted to buy need your shareinvestor88 permission ???....



Please don't use Keyman188 as accuse to cheat members here....


Very very soon karma will come to you shareinvestor88...Keyman188 worry shareholder88 whole family will be infected Covid-19 soon......


Keyman188 need to highlight again, don't use Keyman188 as accuse to cheat members......


Very very soon karma will come to you shareinvestor88...Keyman188 worry shareholder88 whole family will be infected Covid-19 soon......


Now more worst, karma very soon come to see you, shareinstor88, whole family soon crash at accidental & become koma (half live half death)...kesian...kesian...



Posted by shareinvestor88 > Jul 27, 2020 10:04 PM | Report Abuse 

keyman , buy bye more Lai Lai Lai

Lai...lai...lai....Don't talk 3 talk 4 talk cock....

Long waiting for que level...

3.91 (done)

3.86

3.81

3.76

3.71

3.66

3.61


Keyman188 still holding old stock @ 3.03 since March'20 turbulence time until now...

Keyman188 already earned handsome profit since March'20 until now...

Keyman188 always is the mad mad investors + traders......

Other people pandemic selling down....Keyman188 madness collecting fall knight.....

Smart investors + traders always know how to position their investment portfolio...


Lai...lai...lai

Keyman188 foresee a lot of traders & investors will surprised by this 2 core pharmaceutical firms which dealing with Covid-19 vaccine will be reaching unprecedented level :-

1) Pharma - TP 10.00

2) Dpharma - TP 7.50


Keyman188 looking at long term growth due to following reason (which were highlighted by Minister) :-


1) Two government-linked companies (GLC) which are also pharmaceutical manufacturing facilities have been identified to do the "fill and finish" process for the Covid-19 vaccine once it's available


2) "The two companies have told the government that they are willing to take stock production and prioritise it for the Covid-19 vaccine when it is available.


3) If we have the capacity, we will also offer our fill and finish service to other countries.


---------------------------------------------------------------------------------------------------


A lot of investors & traders not review the past annual report for Duopharma

Gross Profit margin always can generated by 40% from the revenue

Net profit also improved by 11% to 13% since 2018

Forthcoming financial performance more & more bright of this pharmaceutical firm since already appointed core company dealing with Covid-19 vaccine once available


---------------------------------------------------------------------------------------------------



@@ Keyman188 always like to repeat & repeat to remind "old people" like Keyman188 to avoid forgotten........


## Hopefully for those so negative of this company, faster contribute to Keyman188 everyday trading day......

Stay tuned.....Sooner or later (not far away)......more & more people sure "sakit hati"......kekeke...kekeke...

wkwkwk...wkwkwk...Do more study...Do more research...Do more explore...

------------------------------------------------------------------------------------------

Not the Keyman188 comments, all from professionals & experts......


""However, Nomura does not see solvency risk as the group has RM6.5bil cash, while net debt-to-equity stood at 25% as of end-1Q20. This, according to Nomura, assumes the pandemic is broadly under control and the new outdoor theme park opens some time by 2021.""

------------------------------------------------------------------------------------------

HLG IB target: 4.77

PBB IB target : 4.70

Kenanga IB target : 4.90


*** Sound like familiar....Keyman188 don't know where heard about this....kekek...kekeke....


Not Keyman188 word (I copycat from other comment)...kekeke...kekeke...

Some time need to repeat a few times to avoid stubborn 'old' people forgot...wkwkwk...


------------------------------------------------------------------------------------------


你己经开始怀疑人生了吗!!!...You have begun to doubt your life !!!......

Kekeke...kekeke...kekeke....

------------------------------------------------------------------------------------------


人生錯过了一次就够了，別错过第二次......

One missed life is enough, don’t miss the second time......

Keyman188 when to buy...how to buy...why Keyman188 wanted to buy need your shareinvestor88 permission ???....



Please don't use Keyman188 as accuse to cheat members here....


Very very soon karma will come to you shareinvestor88...Keyman188 worry shareholder88 whole family will be infected Covid-19 soon......


Keyman188 need to highlight again, don't use Keyman188 as accuse to cheat members......


Very very soon karma will come to you shareinvestor88...Keyman188 worry shareholder88 whole family will bebinfected Covid-19 soon......





Posted by shareinvestor88 > Jul 26, 2020 6:40 PM | Report Abuse

keyman 188 can bye more?


Posted by shareinvestor88 > Jul 26, 2020 10:25 PM | Report Abuse

KEYMAN188 PLEASE BUY MORE AT THIS PRICE

Keyman188 foresee a lot of traders & investors will surprised by this 2 core pharmaceutical firms which dealing with Covid-19 vaccine will be reaching unprecedented level :-

1) Pharma - TP 10.00

2) Dpharma - TP 7.50


Keyman188 looking at long term growth due to following reason (which were highlighted by Minister) :-


1) Two government-linked companies (GLC) which are also pharmaceutical manufacturing facilities have been identified to do the "fill and finish" process for the Covid-19 vaccine once it's available


2) "The two companies have told the government that they are willing to take stock production and prioritise it for the Covid-19 vaccine when it is available.


3) If we have the capacity, we will also offer our fill and finish service to other countries.


---------------------------------------------------------------------------------------------------


A lot of investors & traders not review the past annual report for Duopharma

Gross Profit margin always can generated by 40% from the revenue

Net profit also improved by 11% to 13% since 2018

Forthcoming financial performance more & more bright of this pharmaceutical firm since already appointed core company dealing with Covid-19 vaccine once available


---------------------------------------------------------------------------------------------------



@@ Keyman188 always like to repeat & repeat to remind "old people" like Keyman188 to avoid forgotten........


## Hopefully for those so negative of this company, faster contribute to Keyman188 everyday trading day......

Stay tuned.....Sooner or later (not far away)......more & more people sure "sakit hati"......kekeke...kekeke...

wkwkwk...wkwkwk...Do more study...Do more research...Do more explore...

------------------------------------------------------------------------------------------

Not the Keyman188 comments, all from professionals & experts......


""However, Nomura does not see solvency risk as the group has RM6.5bil cash, while net debt-to-equity stood at 25% as of end-1Q20. This, according to Nomura, assumes the pandemic is broadly under control and the new outdoor theme park opens some time by 2021.""

------------------------------------------------------------------------------------------

HLG IB target: 4.77

PBB IB target : 4.70

Kenanga IB target : 4.90


*** Sound like familiar....Keyman188 don't know where heard about this....kekek...kekeke....


Not Keyman188 word (I copycat from other comment)...kekeke...kekeke...

Some time need to repeat a few times to avoid stubborn 'old' people forgot...wkwkwk...


------------------------------------------------------------------------------------------


你己经开始怀疑人生了吗!!!...You have begun to doubt your life !!!......

Kekeke...kekeke...kekeke....

------------------------------------------------------------------------------------------


人生錯过了一次就够了，別错过第二次......

One missed life is enough, don’t miss the second time......

Malaysia, Singapore hold historic causeway meet, Aug 17 cross-border travel resumption likely

July 26, 2020 12:06 pm +08

JOHOR BARU (July 26): The foreign ministers of Malaysia and Singapore today held a historic meeting at the midway point of the Johor Causeway and agreed to resume as early as Aug 17 cross-border travel that had been denied since March by the Covid-19 pandemic.

The 10-minute meeting between Datuk Seri Hishammuddin Hussein and Singapore Foreign Minister Dr Vivian Balakrishnan was the first physical one to be held after the two countries closed their borders to contain the pandemic, starting with Malaysia after it implemented the movement control order (MCO) on March 18.

Describing the meeting as one for the history books, Hishammuddin said the successful discussion that will soon lead to the reopening of the borders can be used as a "template" for talks with other nations as well on matters concerning international travel.

“This meeting was specifically aimed at discussing the Reciprocal Green Lane (RGL) and Periodic Commuting Arrangement (PCA).

“We have reached an agreement where standard operating procedures on both sides have been finalised as well,” he told reporters at the conclusion of the meeting here today. Johor Menteri Besar Datuk Ir Hasni Mohammad was also present.

With this new development, Malaysians eligible for both categories can submit their applications to the Immigration Department from Aug 10, Hishammuddin said.

“As for the third and fourth schemes, both governments need to fine-tune a number of things before they can be implemented. They are more towards security and health issues as Covid-19 is still a concern,” he added.

Standard operating procedure (SOP) compliance and good self-discipline during cross border travel under the RGL and PCA categories will determine whether the third and fourth categories will be agreed upon as well, Hishammuddin pointed out.

Movement under the third and fourth categories will also test the abilities of the two countries in conducting Covid-19 screenings, he added.

Besides Singapore, Malaysia is also in discussions with Australia, New Zealand, Thailand, Brunei and Japan on the implementation of the "green bubble" travel concept.


##https://www.theedgemarkets.com/article/malaysiasingapore-travel-begin-earliest-aug-17-says-hishammuddin

Malaysia, Singapore hold historic causeway meet, Aug 17 cross-border travel resumption likely

July 26, 2020 12:06 pm +08

JOHOR BARU (July 26): The foreign ministers of Malaysia and Singapore today held a historic meeting at the midway point of the Johor Causeway and agreed to resume as early as Aug 17 cross-border travel that had been denied since March by the Covid-19 pandemic.

The 10-minute meeting between Datuk Seri Hishammuddin Hussein and Singapore Foreign Minister Dr Vivian Balakrishnan was the first physical one to be held after the two countries closed their borders to contain the pandemic, starting with Malaysia after it implemented the movement control order (MCO) on March 18.

Describing the meeting as one for the history books, Hishammuddin said the successful discussion that will soon lead to the reopening of the borders can be used as a "template" for talks with other nations as well on matters concerning international travel.

“This meeting was specifically aimed at discussing the Reciprocal Green Lane (RGL) and Periodic Commuting Arrangement (PCA).

“We have reached an agreement where standard operating procedures on both sides have been finalised as well,” he told reporters at the conclusion of the meeting here today. Johor Menteri Besar Datuk Ir Hasni Mohammad was also present.

With this new development, Malaysians eligible for both categories can submit their applications to the Immigration Department from Aug 10, Hishammuddin said.

“As for the third and fourth schemes, both governments need to fine-tune a number of things before they can be implemented. They are more towards security and health issues as Covid-19 is still a concern,” he added.

Standard operating procedure (SOP) compliance and good self-discipline during cross border travel under the RGL and PCA categories will determine whether the third and fourth categories will be agreed upon as well, Hishammuddin pointed out.

Movement under the third and fourth categories will also test the abilities of the two countries in conducting Covid-19 screenings, he added.

Besides Singapore, Malaysia is also in discussions with Australia, New Zealand, Thailand, Brunei and Japan on the implementation of the "green bubble" travel concept.


##https://www.theedgemarkets.com/article/malaysiasingapore-travel-begin-earliest-aug-17-says-hishammuddin

A lot of investors & traders not review the past annual report

Gross Profit margin always can generated by 40% from the revenue

Net profit also improved by 11% to 13% since 2018

Forthcoming financial performance more & more bright of this pharmaceutical firm since already appointed core company dealing with Covid-19 vaccine once available

Next week, Keyman188 hopefully more negative news to press down the share price until Keyman188 desire level to bet in again...